Your browser is no longer supported. Please, upgrade your browser.
Prothena Corporation plc
Index- P/E45.06 EPS (ttm)1.03 Insider Own0.05% Shs Outstand45.63M Perf Week-5.22%
Market Cap2.31B Forward P/E- EPS next Y-2.06 Insider Trans-92.32% Shs Float23.58M Perf Month-21.54%
Income69.40M PEG- EPS next Q-0.84 Inst Own89.50% Short Float7.23% Perf Quarter-34.73%
Sales199.80M P/S11.58 EPS this Y-43.00% Inst Trans1.31% Short Ratio5.25 Perf Half Y25.14%
Book/sh10.75 P/B4.33 EPS next Y-255.90% ROA15.60% Target Price82.22 Perf Year323.55%
Cash/sh12.08 P/C3.86 EPS next 5Y-0.60% ROE23.20% 52W Range10.72 - 79.75 Perf YTD287.93%
Dividend- P/FCF24.18 EPS past 5Y-0.90% ROI-61.10% 52W High-41.58% Beta1.23
Dividend %- Quick Ratio20.80 Sales past 5Y-11.90% Gross Margin- 52W Low334.61% ATR4.11
Employees66 Current Ratio20.80 Sales Q/Q30705.60% Oper. Margin37.50% RSI (14)35.49 Volatility9.85% 7.79%
OptionableYes Debt/Eq0.00 EPS Q/Q378.50% Profit Margin34.80% Rel Volume1.27 Prev Close49.67
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout0.00% Avg Volume324.67K Price46.59
Recom1.60 SMA20-14.64% SMA50-24.08% SMA2000.86% Volume413,846 Change-6.20%
Nov-19-21Initiated JMP Securities Mkt Outperform $77
Jun-18-21Upgrade BofA Securities Underperform → Neutral $12 → $49
Jun-08-21Reiterated Oppenheimer Outperform $45 → $54
May-26-21Initiated Citigroup Buy $39
Feb-26-21Upgrade RBC Capital Mkts Sector Perform → Outperform $14 → $28
Feb-12-21Upgrade Jefferies Hold → Buy $15 → $30
Feb-02-21Upgrade BTIG Research Neutral → Buy $29
Dec-07-20Initiated H.C. Wainwright Buy $22
Jul-09-20Upgrade Oppenheimer Perform → Outperform $16
Nov-19-19Upgrade Evercore ISI In-line → Outperform $14
May-21-18Downgrade Barclays Equal Weight → Underweight $14 → $12
Apr-23-18Downgrade Jefferies Buy → Hold
Apr-05-18Reiterated Barclays Overweight $70 → $50
Nov-20-17Downgrade Wedbush Outperform → Neutral $75 → $55
Sep-29-17Reiterated BTIG Research Buy $80 → $77
Sep-15-17Initiated RBC Capital Mkts Outperform $87
Aug-17-17Initiated Evercore ISI Outperform $83
Jul-11-17Initiated Jefferies Buy
Apr-12-17Initiated Piper Jaffray Overweight $69
Apr-12-17Initiated Cantor Fitzgerald Overweight $86
Nov-29-21 04:05PM  
Nov-25-21 08:25AM  
Nov-22-21 10:38AM  
Nov-18-21 08:43AM  
Nov-10-21 09:14AM  
Nov-05-21 08:59AM  
Nov-04-21 08:56PM  
Nov-01-21 11:26AM  
Oct-28-21 04:05PM  
Oct-27-21 03:03PM  
Oct-26-21 02:03PM  
Oct-23-21 06:08AM  
Oct-15-21 09:34AM  
Oct-12-21 11:40AM  
Oct-11-21 01:06PM  
Oct-04-21 11:54AM  
Oct-01-21 04:30PM  
Sep-23-21 11:40AM  
Sep-18-21 09:13AM  
Sep-09-21 12:00PM  
Sep-03-21 04:05PM  
Sep-01-21 04:05PM  
Aug-25-21 04:46AM  
Aug-11-21 08:02AM  
Aug-09-21 01:32AM  
Aug-06-21 12:41PM  
Aug-05-21 05:25PM  
Aug-03-21 11:33AM  
Jul-29-21 04:05PM  
Jul-26-21 03:27PM  
Jul-20-21 04:05PM  
Jul-17-21 07:37AM  
Jul-16-21 11:40AM  
Jul-14-21 03:21PM  
Jul-13-21 12:22PM  
Jul-12-21 12:45PM  
Jun-24-21 08:30AM  
Jun-18-21 04:53AM  
Jun-10-21 04:19PM  
Jun-09-21 04:58AM  
May-20-21 04:05PM  
May-12-21 03:32PM  
May-11-21 04:05PM  
May-10-21 04:05PM  
May-07-21 04:05PM  
May-04-21 04:05PM  
Apr-28-21 12:33PM  
Apr-18-21 03:05PM  
Apr-15-21 04:05PM  
Apr-07-21 04:05PM  
Apr-05-21 04:05PM  
Mar-29-21 08:22AM  
Mar-25-21 11:37AM  
Mar-24-21 08:00AM  
Mar-23-21 04:29PM  
Mar-13-21 10:30AM  
Mar-11-21 08:19AM  
Mar-08-21 04:05PM  
Feb-24-21 04:05PM  
Feb-12-21 05:11PM  
Feb-11-21 09:19AM  
Feb-05-21 04:05PM  
Feb-04-21 04:05PM  
Feb-03-21 12:30PM  
Feb-01-21 04:15PM  
Dec-09-20 08:00AM  
Dec-04-20 04:05PM  
Nov-27-20 12:25AM  
Nov-16-20 02:56AM  
Nov-05-20 11:13AM  
Nov-04-20 06:35PM  
Oct-28-20 04:05PM  
Oct-21-20 10:48AM  
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; A, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker Karin LChief Accounting OfficerNov 23Option Exercise15.044,51967,9664,519Nov 26 09:19 PM
Walker Karin LChief Accounting OfficerNov 23Sale57.884,519261,5730Nov 26 09:19 PM
Malecek Michael JSee RemarksNov 19Option Exercise10.2710,000102,70010,000Nov 19 09:32 PM
Malecek Michael JSee RemarksNov 19Sale55.0010,000550,0000Nov 19 09:32 PM
Karp Carol D.Chief Regulatory OfficerNov 01Option Exercise15.0410,000150,40010,000Nov 03 09:17 PM
Karp Carol D.Chief Regulatory OfficerNov 01Sale57.1810,000571,8180Nov 03 09:17 PM
Malecek Michael JSee RemarksOct 27Option Exercise10.2710,000102,70010,000Oct 29 05:00 PM
Malecek Michael JSee RemarksOct 27Sale58.5210,000585,2500Oct 29 05:00 PM
Walker Karin LChief Accounting OfficerOct 20Option Exercise16.9723,000390,23023,000Oct 22 05:53 PM
Walker Karin LChief Accounting OfficerOct 20Sale60.2523,0001,385,8230Oct 22 05:53 PM
Karp Carol D.Chief Regulatory OfficerOct 01Option Exercise15.0410,000150,40010,000Oct 01 08:46 PM
Selkoe Dennis J.DirectorOct 01Option Exercise9.235,00046,1507,845Oct 01 09:18 PM
Selkoe Dennis J.DirectorOct 01Sale67.845,000339,1762,845Oct 01 09:18 PM
Karp Carol D.Chief Regulatory OfficerOct 01Sale68.2310,000682,3360Oct 01 08:46 PM
Karp Carol D.Chief Regulatory OfficerSep 09Option Exercise15.0410,000150,40010,000Sep 10 05:06 PM
Karp Carol D.Chief Regulatory OfficerSep 09Sale71.9810,000719,8470Sep 10 05:06 PM
Selkoe Dennis J.DirectorJul 30Option Exercise14.265,00071,3157,845Jul 30 08:04 PM
Selkoe Dennis J.DirectorJul 30Sale49.475,000247,3742,845Jul 30 08:04 PM
HENNEY CHRISTOPHER SDirectorJul 14Option Exercise11.3311,108125,85411,108Jul 16 04:02 PM
HENNEY CHRISTOPHER SDirectorJul 14Sale55.4611,108616,0200Jul 16 04:02 PM
HENNEY CHRISTOPHER SDirectorJul 12Option Exercise9.7923,892233,94617,500Jul 12 09:37 PM
HENNEY CHRISTOPHER SDirectorJul 12Sale55.5123,8921,326,1280Jul 12 09:37 PM
HENNEY CHRISTOPHER SDirectorJun 25Option Exercise16.4312,000197,16012,000Jun 29 06:13 PM
HENNEY CHRISTOPHER SDirectorJun 25Sale47.7312,000572,8190Jun 29 06:13 PM
Zago Wagner M.Chief Scientific OfficerJun 22Option Exercise17.81115,2502,052,940115,250Jun 24 04:38 PM
Zago Wagner M.Chief Scientific OfficerJun 22Sale46.15115,2505,318,7690Jun 24 04:38 PM
EcoR1 Capital, LLC10% OwnerMar 24Buy20.75875,00018,156,25011,034,280Mar 25 11:14 AM
EcoR1 Capital, LLC10% OwnerFeb 24Buy22.0210,800237,86710,159,280Feb 25 06:00 PM
EcoR1 Capital, LLC10% OwnerFeb 23Buy21.0544,400934,51810,148,480Feb 25 06:00 PM
Zago Wagner M.Chief Scientific OfficerFeb 18Option Exercise6.417,54048,3317,540Feb 19 06:39 PM
EcoR1 Capital, LLC10% OwnerFeb 18Buy3.6844,100162,10310,104,080Feb 22 04:24 PM
Zago Wagner M.Chief Scientific OfficerFeb 18Sale25.507,540192,2700Feb 19 06:39 PM
EcoR1 Capital, LLC10% OwnerFeb 17Buy23.46198,8404,665,54210,059,980Feb 17 07:14 PM
EcoR1 Capital, LLC10% OwnerFeb 16Buy22.7889,2002,031,9679,861,140Feb 17 07:14 PM
Zago Wagner M.Chief Scientific OfficerFeb 12Option Exercise11.4826,310302,14718,750Feb 17 06:47 PM
EcoR1 Capital, LLC10% OwnerFeb 12Buy20.16345,3006,959,7619,771,940Feb 17 07:14 PM
Zago Wagner M.Chief Scientific OfficerFeb 12Sale19.1626,310504,0570Feb 17 06:47 PM